Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $2.7 million.

  • Rocket Pharmaceuticals' Other Accumulated Expenses fell 350.18% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 350.18%. This contributed to the annual value of $1.6 million for FY2024, which is 829.57% down from last year.
  • Rocket Pharmaceuticals' Other Accumulated Expenses amounted to $2.7 million in Q3 2025, which was down 350.18% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Other Accumulated Expenses registered a high of $3.1 million during Q2 2024, and its lowest value of $482000.0 during Q4 2021.
  • Over the past 5 years, Rocket Pharmaceuticals' median Other Accumulated Expenses value was $1.7 million (recorded in 2025), while the average stood at $1.7 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Other Accumulated Expenses surged by 37157.68% in 2022 and then plummeted by 4416.86% in 2025.
  • Rocket Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $482000.0 in 2021, then skyrocketed by 371.58% to $2.3 million in 2022, then dropped by 22.04% to $1.8 million in 2023, then dropped by 8.3% to $1.6 million in 2024, then skyrocketed by 64.49% to $2.7 million in 2025.
  • Its Other Accumulated Expenses stands at $2.7 million for Q3 2025, versus $1.7 million for Q2 2025 and $2.9 million for Q1 2025.